PMID- 31190749
OWN - NLM
STAT- MEDLINE
DCOM- 20200120
LR  - 20200225
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - Subcutaneous bortezomib might be standard of care for patients with multiple 
      myeloma: a systematic review and meta-analysis.
PG  - 1707-1716
LID - 10.2147/DDDT.S198117 [doi]
AB  - Background: Administration of subcutaneous (SC) bortezomib in patients with 
      multiple myeloma (MM) has increased in recent years. Yet, it is unclear whether 
      there is sufficient evidence to support the use of SC bortezomib as a standard of 
      care. Methods: A systematic review of 4 randomized controlled trials and 8 
      retrospective trials comparing SC to intravenous (IV) bortezomib among 1,857 MM 
      patients was performed. Embase, PubMed, Clinical Trials.gov, Cochrane Library and 
      reference lists were searched for relevant studies from inception until August 
      2018. Outcomes of interest included 1-year overall survival (OS), 1-year 
      progression-free survival (PFS), objective response rate (ORR) and adverse events 
      (AEs). Random events meta-analyses were performed. We also performed sensitivity 
      analysis to examine whether the results of the meta-analysis were robust. 
      Results: Compared to IV administration, SC bortezomib had a significantly lower 
      incidence of some all-grade or grade 3-4 AE, such as peripheral sensory 
      neuropathy, leukopenia and thrombocytopenia (p<0.05). There was no statistical 
      difference in 1-year OS, 1-year PFS, ORR between SC and IV bortezomib (p>0.05). 
      Conclusion: The data presented so far consistently show that SC bortezomib has 
      become a standard of care for patients with MM.
FAU - Ye, Ziqi
AU  - Ye Z
AD  - Department of Pharmacy, the First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Pharmacy, the Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, People's Republic of China.
FAU - Xuan, Zixue
AU  - Xuan Z
AD  - Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, People's 
      Republic of China.
FAU - Yang, Wenchao
AU  - Yang W
AD  - Department of Pharmacy, Traditional Chinese Medical Hospital of Zhuji, Zhuji, 
      People's Republic of China.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Medical Oncology, the First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190516
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Administration, Intravenous
MH  - Bortezomib/*administration & dosage/*therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Multiple Myeloma/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - *Standard of Care
PMC - PMC6529723
OTO - NOTNLM
OT  - adverse events
OT  - efficacy
OT  - intravenous bortezomib
OT  - multiple myeloma
OT  - subcutaneous bortezomib
OT  - systematic review
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/14 06:00
MHDA- 2020/01/21 06:00
PMCR- 2019/05/16
CRDT- 2019/06/14 06:00
PHST- 2018/12/13 00:00 [received]
PHST- 2019/04/03 00:00 [accepted]
PHST- 2019/06/14 06:00 [entrez]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2020/01/21 06:00 [medline]
PHST- 2019/05/16 00:00 [pmc-release]
AID - 198117 [pii]
AID - 10.2147/DDDT.S198117 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 May 16;13:1707-1716. doi: 10.2147/DDDT.S198117. 
      eCollection 2019.